Afficher la couverture 'Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis | van Sanden, Suzy' en grand format
/5

0 avis

Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis

Archive ouverte

van Sanden, Suzy | Murton, Molly | Bobrowska, Anna | Rahhali, Nora | Sermon, Jan | Rodrigues, Bernardo | Goff-Leggett, Danielle | Chouaid, Christos | Sebastian, Martin | Greystoke, Alastair

Edité par CCSD ; Springer Verlag (Germany) -

International audience. Background Information on the epidemiology of uncommon EGFR mutations including exon 20 insertions amongst nonsmall-cell lung cancer (NSCLC) is lacking. Objective The objective of this pragmatic literature review (PLR) and meta-analysis was to generate robust prevalence and incidence estimates based on ranges of exon 20 insertion mutations reported in the literature. Materials and methods Searches of MEDLINE, Embase, congresses and reference lists for articles published from 2013 in key European countries of interest

Suggestions

Du même auteur

Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study

Archive ouverte | Thiery-Vuillemin, Antoine | CCSD

International audience. Background: Few studies have examined patient-reported outcomes (PROs) with abiraterone acetate plus prednisone (abiraterone) versus enzalutamide in metastatic castration-resistant prostate c...

An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Archive ouverte | Chouaid, Christos | CCSD

International audience. Introduction: Patients with advanced, epidermal growth factor receptor (EGFR)-mutated, non-small cell lung cancer (NSCLC) with Exon 20 insertion mutations (Exon20ins) have poor prognoses, exa...

Amivantamab Compared with Real-World Physician’s Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations

Archive ouverte | Christopoulos, Petros D. | CCSD

International audience. Patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor gene (EGFR) Exon 20 insertions (Exon20ins) at the second line and beyond (2L+) have an unmet ne...

Chargement des enrichissements...